Last reviewed · How we verify
Placebo to ERN/LRPT
This drug is a placebo, meaning it has no active therapeutic effect.
This drug is a placebo, meaning it has no active therapeutic effect. Used for Treatment of symptoms in clinical trials.
At a glance
| Generic name | Placebo to ERN/LRPT |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological molecules or systems, and its effects are purely psychological or due to the natural course of the disease.
Approved indications
- Treatment of symptoms in clinical trials
Common side effects
- No adverse events
Key clinical trials
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (PHASE3)
- Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease (PHASE4)
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) (PHASE3)
- The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients (PHASE4)
- Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) (PHASE3)
- A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to ERN/LRPT CI brief — competitive landscape report
- Placebo to ERN/LRPT updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI